Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership3,142,175 shares
Ownership 4.90%
Goldman Sachs Group Inc ownership in TVTX / Travere Therapeutics, Inc.

2023-02-10 - Goldman Sachs Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,142,175 shares of Travere Therapeutics, Inc. (US:TVTX). This represents 4.9 percent ownership of the company. In their previous filing dated 2022-02-01 , Goldman Sachs Group Inc had reported owning 4,599,279 shares, indicating a decrease of -31.68 percent.

Goldman Sachs Group Inc has a history of taking positions in derivatives of the underlying security (TVTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2023-02-10 2023-02-10 13G/A 4,599,279 3,142,175 -31.68 4.90 -34.67
2022-02-01 2022-02-01 13G 696,852 4,599,279 560.01 7.50 316.67
2017-02-10 2017-02-10 13G/A 1,945,467 696,852 -64.18 1.80 -66.67
2016-02-09 2016-02-09 13G 1,945,467 5.40

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TVTX / Travere Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 1,719,721 -148,491 -7.95 51,093 -28.43 0.0014
2026-02-10 2025-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 1,868,212 594,309 46.65 71,384 134.46 0.0088
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS CMN 89422G107 1,273,903 -282,949 -18.17 30,446 32.14 0.0037
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS CMN 89422G107 1,556,852 689,210 79.43 23,041 48.19 0.0031
2025-06-27 2025-03-31 13F/A-2 TRAVERE THERAPEUTICS CMN 89422G107 867,642 -63,370 -6.81 15,548 -4.13 0.0025
2025-05-16 2025-03-31 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 867,642 -63,370 15,548 0.0006
2025-05-09 2025-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 1,082,642 151,630 19,401 0.0006
2025-02-11 2024-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 931,012 228,406 32.51 16,218 65.00 0.0026
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS CMN 89422G107 702,606 -76,043 -9.77 9,829 53.58 0.0016
2024-08-13 2024-06-30 13F TRAVERE THERAPEUTICS CMN 89422G107 778,649 59,782 8.32 6,400 15.48 0.0011
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 718,867 -771,881 -51.78 5,542 -58.64 0.0010
2024-05-14 2023-12-31 13F/A-2 TRAVERE THERAPEUTICS CMN 89422G107 1,490,748 -21,339 -1.41 13,402 -0.87 0.0025
2024-03-01 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 1,490,748 13,402
2024-02-13 2023-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 1,490,748 -21,339 13,402 0.0024
2024-05-15 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 1,512,087 588,196 63.67 13,518 -4.74 0.0029
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS CMN 89422G107 1,512,087 588,196 13,518 0.0027
2024-05-14 2023-06-30 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 923,891 132,663 16.77 14,191 -20.25 0.0030
2023-08-15 2023-06-30 13F TRAVERE THERAPEUTICS CMN 89422G107 923,891 132,663 14,191 0.0029
2024-05-14 2023-03-31 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 791,228 -1,848,918 -70.03 17,795 -67.95 0.0041
2023-05-11 2023-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 791,228 -1,848,918 17,795 0.0038
2024-05-14 2022-12-31 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 2,640,146 86,172 3.37 55,522 89,451.61 0.0136
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 2,640,146 86,172 55,522 0.0124
2024-05-14 2022-09-30 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 2,553,974 -58,672 -2.25 63 -1.59 0.0159
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS CMN 89422G107 2,553,974 -58,672 62,930 0.0145
2024-05-14 2022-06-30 13F/A-2 TRAVERE THERAPEUTICS CMN 89422G107 2,612,646 22,539 0.87 63 -99.91 0.0158
2022-08-18 2022-06-30 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 2,612,646 22,539 63,305 0.0143
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS CMN 89422G107 2,612,646 22,539 63,305 0.0143
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 2,590,107 -3,650 -0.14 66,747 -17.09 0.0140
2022-02-17 2021-12-31 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 2,593,757 1,500,435 137.24 80,510 203.66 0.0160
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 2,593,757 1,500,435 80,510 0.0046
2022-01-20 2021-09-30 13F/A-1 TRAVERE THERAPEUTICS CMN 89422G107 1,093,322 -1,363,958 -55.51 26,513 -26.05 0.0056
2021-11-10 2021-09-30 13F TRAVERE THERAPEUTICS CMN 89422G107 1,093,322 -1,363,958 26,513 0.0016
2021-08-13 2021-06-30 13F TRAVERE THERAPEUTICS CMN 89422G107 2,457,280 1,629,846 196.98 35,852 73.52 0.0080
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS CMN 89422G107 827,434 113,468 15.89 20,661 6.18 0.0052
2021-02-12 2020-12-31 13F TRAVERE THERAPEUTICS CMN 89422G107 713,966 48,891 7.35 19,459 58.50 0.0050
2020-11-13 2020-09-30 13F RETROPHIN CMN 761299106 665,075 -187,774 -22.02 12,277 -29.47 0.0035
2020-08-12 2020-06-30 13F RETROPHIN CMN 761299106 852,849 149,359 21.23 17,407 69.59 0.0053
2020-05-15 2020-03-31 13F RETROPHIN CMN 761299106 703,490 578,306 461.96 10,264 477.60 0.0036
2020-02-14 2019-12-31 13F RETROPHIN CMN 761299106 125,184 65,934 111.28 1,777 158.66 0.0005
2019-11-14 2019-09-30 13F RETROPHIN CMN 761299106 59,250 -341,004 -85.20 687 -91.46 0.0002
2019-08-14 2019-06-30 13F RETROPHIN CMN 761299106 400,254 -19,990 -4.76 8,041 -15.45 0.0023
2019-05-15 2019-03-31 13F RETROPHIN CMN 761299106 420,244 -151,126 -26.45 9,510 -26.45 0.0029
2019-02-14 2018-12-31 13F RETROPHIN CMN 761299106 571,370 -111,046 -16.27 12,930 -34.05 0.0041
2018-11-14 2018-09-30 13F RETROPHIN CMN 761299106 682,416 148,276 27.76 19,606 34.65 0.0051
2018-08-14 2018-06-30 13F RETROPHIN CMN 761299106 534,140 -566 -0.11 14,561 21.79 0.0039
2018-05-15 2018-03-31 13F RETROPHIN CMN 761299106 534,706 -76,856 -12.57 11,956 -7.21 0.0031
2018-02-14 2017-12-31 13F RETROPHIN CMN 761299106 611,562 17,255 2.90 12,885 -12.89 0.0031
2017-11-14 2017-09-30 13F RETROPHIN CMN 761299106 594,307 87,503 17.27 14,792 50.52 0.0036
2017-08-14 2017-06-30 13F RETROPHIN CMN 761299106 506,804 182,880 56.46 9,827 64.33 0.0025
2017-05-18 2017-03-31 13F/A-1 RETROPHIN CMN 761299106 323,924 -171,663 -34.64 5,980 -36.25 0.0016
2017-05-15 2017-03-31 13F RETROPHIN CMN 761299106 323,924 5,980
2017-02-14 2016-12-31 13F RETROPHIN CMN 761299106 495,587 -44,651 -8.27 9,381 -22.41 0.0027
2016-11-14 2016-09-30 13F RETROPHIN CMN 761299106 540,238 -323,762 -37.47 12,090 -21.43 0.0037
2016-08-15 2016-06-30 13F RETROPHIN CMN 761299106 864,000 41,573 5.05 15,388 36.98 0.0050
2016-05-13 2016-03-31 13F RETROPHIN CMN 761299106 822,427 302,245 58.10 11,234 11.96 0.0037
2016-02-16 2015-12-31 13F RETROPHIN CMN 761299106 520,182 17,130 3.41 10,034 -1.55 0.0031
2015-11-13 2015-09-30 13F RETROPHIN CMN 761299106 503,052 487,267 3,086.90 10,192 1,848.76 0.0034
2015-08-14 2015-06-30 13F RETROPHIN CMN 761299106 15,785 -471,277 -96.76 523 -95.52 0.0002
2015-05-15 2015-03-31 13F RETROPHIN CMN 761299106 487,062 278,263 133.27 11,670 356.57 0.0038
2015-02-13 2014-12-31 13F RETROPHIN CMN 761299106 208,799 181,635 668.66 2,556 943.27 0.0008
2014-11-14 2014-09-30 13F RETROPHIN CMN 761299106 27,164 27,164 245 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-16 2025-03-31 13F/A TRAVERE THERAPEUTICS CMN Call 215,000 3,853 n/a n/a n/a
2025-06-27 2025-03-31 13F/A TRAVERE THERAPEUTICS CMN Call 215,000 3,853 n/a n/a n/a
2019-11-14 2019-09-30 13F RETROPHIN CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-08-14 2019-06-30 13F RETROPHIN CMN Call 53,400 206.90 1,073 172.34 n/a n/a n/a
2019-05-15 2019-03-31 13F RETROPHIN CMN Call 17,400 394 n/a n/a n/a
2019-02-14 2018-12-31 13F RETROPHIN CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F RETROPHIN CMN Call 800 0.00 23 4.55 n/a n/a n/a
2018-08-14 2018-06-30 13F RETROPHIN CMN Call 800 22 n/a n/a n/a
2018-05-15 2018-03-31 13F RETROPHIN CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-02-14 2017-12-31 13F RETROPHIN CMN Call 263,900 -0.64 5,560 -15.90 n/a n/a n/a
2017-11-14 2017-09-30 13F RETROPHIN CMN Call 265,600 -0.67 6,611 27.50 n/a n/a n/a
2017-08-14 2017-06-30 13F RETROPHIN CMN Call 267,400 1.10 5,185 6.18 n/a n/a n/a
2017-05-18 2017-03-31 13F/A RETROPHIN CMN Call 264,500 0.42 4,883 -2.07 n/a n/a n/a
2017-05-15 2017-03-31 13F RETROPHIN CMN Call 264,500 4,883 n/a n/a n/a
2017-02-14 2016-12-31 13F RETROPHIN CMN Call 263,400 -9.27 4,986 -23.26 n/a n/a n/a
2016-11-14 2016-09-30 13F RETROPHIN CMN Call 290,300 8,438.24 6,497 10,550.82 n/a n/a n/a
2016-08-15 2016-06-30 13F RETROPHIN CMN Call 3,400 25.93 61 64.86 n/a n/a n/a
2016-05-13 2016-03-31 13F RETROPHIN CMN Call 2,700 -99.81 37 -99.87 n/a n/a n/a
2016-02-16 2015-12-31 13F RETROPHIN CMN Call 1,451,100 -25.52 27,992 -29.08 n/a n/a n/a
2015-11-13 2015-09-30 13F RETROPHIN CMN Call 1,948,200 88.54 39,471 15.23 n/a n/a n/a
2015-08-14 2015-06-30 13F RETROPHIN CMN Call 1,033,300 -3.28 34,254 33.83 n/a n/a n/a
2015-05-15 2015-03-31 13F RETROPHIN CMN Call 1,068,300 612.20 25,596 1,294.12 n/a n/a n/a
2015-02-13 2014-12-31 13F RETROPHIN CMN Call 150,000 1,836 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2018-05-15 2018-03-31 13F RETROPHIN CMN Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-02-14 2017-12-31 13F RETROPHIN CMN Put 1,700 0.00 36 -14.29 n/a n/a n/a
2017-11-14 2017-09-30 13F RETROPHIN CMN Put 1,700 -22.73 42 -2.33 n/a n/a n/a
2017-08-14 2017-06-30 13F RETROPHIN CMN Put 2,200 29.41 43 38.71 n/a n/a n/a
2017-05-18 2017-03-31 13F/A RETROPHIN CMN Put 1,700 -55.26 31 -56.94 n/a n/a n/a
2017-05-15 2017-03-31 13F RETROPHIN CMN Put 1,700 31 n/a n/a n/a
2017-02-14 2016-12-31 13F RETROPHIN CMN Put 3,800 -25.49 72 -36.84 n/a n/a n/a
2016-11-14 2016-09-30 13F RETROPHIN CMN Put 5,100 -99.49 114 -99.35 n/a n/a n/a
2016-08-15 2016-06-30 13F RETROPHIN CMN Put 990,500 -18.12 17,641 6.75 n/a n/a n/a
2016-05-13 2016-03-31 13F RETROPHIN CMN Put 1,209,700 -2.60 16,525 -31.03 n/a n/a n/a
2016-02-16 2015-12-31 13F RETROPHIN CMN Put 1,242,000 -14.94 23,958 -19.02 n/a n/a n/a
2015-11-13 2015-09-30 13F RETROPHIN CMN Put 1,460,200 29,584 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.